LISPRO mitigates β-amyloid and associated pathologies in Alzheimer's mice

Cell Death and Disease

Volumn 8, Issue 6, 2017, Pages

  Habib, Ahsan ^a   Sawmiller, Darrell ^a   Li, Song ^a   Xiang, Yang ^a   Rongo, David ^a   Tian, Jun ^a   Hou, Huayan ^a   Zeng, Jin ^a   Smith, Adam ^a   Fan, Shengnuo ^a   Giunta, Brian ^a   Mori, Takashi ^b   Currier, Glenn ^a   Shytle, Douglas Ronald ^a   Tan, Jun ^a  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

^b SAITAMA MEDICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; CYCLOOXYGENASE 2; GLYCOGEN SYNTHASE KINASE 3BETA; LITHIUM; LITHIUM CARBONATE; LITHIUM DERIVATIVE; LITHIUM SALICYLATE; PROLINE; TAU PROTEIN; UNCLASSIFIED DRUG;

ADULT; ALZHEIMER DISEASE; AMYLOID PLAQUE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; HUMAN CELL; MALE; MOUSE; NERVOUS SYSTEM INFLAMMATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; UPREGULATION; ANIMAL; AUTOPHAGY; BLOOD; CHEMISTRY; HELA CELL LINE; INFLAMMATION; METABOLISM; MICROGLIA; ORAL DRUG ADMINISTRATION; PHAGOCYTOSIS; PHOSPHORYLATION; TRANSGENIC MOUSE; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANIMALS; AUTOPHAGY; GLYCOGEN SYNTHASE KINASE 3 BETA; HELA CELLS; HUMANS; INFLAMMATION; LITHIUM CARBONATE; LITHIUM COMPOUNDS; MALE; MICE; MICE, TRANSGENIC; MICROGLIA; PHAGOCYTOSIS; PHOSPHORYLATION; PROLINE; TREATMENT OUTCOME;

EID: 85020863180     PISSN: None     EISSN: 20414889     Source Type: Journal    
DOI: 10.1038/cddis.2017.279     Document Type: Article

References (61)

1. Masters CL, Simms G, Weinman NA, Multhaup G, McDonald BL, Beyreuther K. Amyloid plaque core protein in Alzheimer disease and Down syndrome. Proc Natl Acad Sci USA 1985; 82: 4245-4249.
2. Grundke-Iqbal I, Iqbal K, Tung YC, Quinlan M, Wisniewski HM, Binder LI. Abnormal phosphorylation of the microtubule-associated protein tau (tau) in Alzheimer cytoskeletal pathology. Proc Natl Acad Sci USA 1986; 83: 4913-4917.
3. Serrano-Pozo A, Frosch MP, Masliah E, Hyman BT. Neuropathological alterations in Alzheimer disease. Cold Spring Harb Perspect Med 2011; 1: a006189.
4. Lleo A. Current therapeutic options for Alzheimer's disease. Curr Genomics 2007; 8: 550-558.
5. Shorter E. The history of lithium therapy. Bipolar Disord 2009; 11: 4-9.
6. Hayes JF, Pitman A, Marston L, Walters K, Geddes JR, King M et al. Self-harm, unintentional injury, and suicide in bipolar disorder during maintenance mood stabilizer treatment: a uk population-based electronic health records study. JAMA Psychiatry 2016; 73: 630-637.
7. Forlenza OV, Diniz BS, Radanovic M, Santos FS, Talib LL, Gattaz WF. Disease-modifying properties of long-term lithium treatment for amnestic mild cognitive impairment: randomised controlled trial. Br J Psychiatry 2011; 198: 351-356.
8. Goodwin FK, Fireman B, Simon GE, Hunkeler EM, Lee J, Revicki D. Suicide risk in bipolar disorder during treatment with lithium and divalproex. JAMA 2003; 290: 1467-1473.
9. Nunes MA, Viel TA, Buck HS. Microdose lithium treatment stabilized cognitive impairment in patients with Alzheimer's disease. Curr Alzheimer Res 2013; 10: 104-107.
10. Phiel CJ, Klein PS. Molecular targets of lithium action. Annu Rev Pharmacol Toxicol 2001; 41: 789-813.
11. Klein PS, Melton DA. A molecular mechanism for the effect of lithium on development. Proc Natl Acad Sci USA 1996; 93: 8455-8459.
12. Mines MA, Jope RS. Glycogen synthase kinase-3: a promising therapeutic target for fragile x syndrome. Front Mol Neurosci 2011; 4: 35.
13. Habib A, Sawmiller D, Tan J. Restoring soluble amyloid precursor protein alpha functions as a potential treatment for Alzheimer's disease. J Neurosci Res 2017; 95: 973-991.
14. Phiel CJ, Wilson CA, Lee VM, Klein PS. GSK-3alpha regulates production of Alzheimer's disease amyloid-beta peptides. Nature 2003; 423: 435-439.
15. Forlenza OV, De-Paula VJ, Diniz BS. Neuroprotective effects of lithium: implications for the treatment of Alzheimer's disease and related neurodegenerative disorders. ACS Chem Neurosci 2014; 5: 443-450.
16. Engel T, Lucas JJ, Gomez-Ramos P, Moran MA, Avila J, Hernandez F. Cooexpression of FTDP-17 tau and GSK-3beta in transgenic mice induce tau polymerization and neurodegeneration. Neurobiol Aging 2006; 27: 1258-1268.
17. Davenport VD. Distribution of parenterally administered lithium in plasma, brain and muscle of rats. Am J Physiol 1950; 163: 633-641.
18. Ebadi MS, Simmons VJ, Hendrickson MJ, Lacy PS. Pharmacokinetics of lithium and its regional distribution in rat brain. Eur J Pharmacol 1974; 27: 324-329.
19. Livingstone C, Rampes H. Lithium: a review of its metabolic adverse effects. J Psychopharmacol 2006; 20: 347-355.
20. Schou M, Baastrup PC, Grof P, Weis P, Angst J. Pharmacological and clinical problems of lithium prophylaxis. Br J Psychiatry 1970; 116: 615-619.
21. Smith AJ, Kim SH, Tan J, Sneed KB, Sanberg PR, Borlongan CV et al. Plasma and brain pharmacokinetics of previously unexplored lithium salts. RSC Adv 2014; 4: 12362-12365.
22. Smith AJ, Kim SH, Duggirala NK, Jin J, Wojtas L, Ehrhart J et al. Improving lithium therapeutics by crystal engineering of novel ionic cocrystals. Mol Pharm 2013; 10: 4728-4738.
23. Yu F, Zhang Y, Chuang DM. Lithium reduces BACE1 overexpression, beta amyloid accumulation, and spatial learning deficits in mice with traumatic brain injury. J Neurotrauma 2012; 29: 2342-2351.
24. Sudduth TL, Wilson JG, Everhart A, Colton CA, Wilcock DM. Lithium treatment of APPSwDI/ NOS2-/-mice leads to reduced hyperphosphorylated tau, increased amyloid deposition and altered inflammatory phenotype. PLoS ONE 2012; 7: e31993.
25. Nikolic WV, Hou H, Town T, Zhu Y, Giunta B, Sanberg CD et al. Peripherally administered human umbilical cord blood cells reduce parenchymal and vascular beta-amyloid deposits in Alzheimer mice. Stem Cells Dev 2008; 17: 423-439.
26. Townsend KP, Town T, Mori T, Lue LF, Shytle D, Sanberg PR et al. CD40 signaling regulates innate and adaptive activation of microglia in response to amyloid beta-peptide. Eur J Immunol 2005; 35: 901-910.
27. Sarkar S, Floto RA, Berger Z, Imarisio S, Cordenier A, Pasco M et al. Lithium induces autophagy by inhibiting inositol monophosphatase. J Cell Biol 2005; 170: 1101-1111.
28. Motoi Y, Shimada K, Ishiguro K, Hattori N. Lithium and autophagy. ACS Chem Neurosci 2014; 5: 434-442.
29. Kwon TH. Dysregulation of renal cyclooxygenase-2 in rats with lithium-induced nephrogenic diabetes insipidus. Electrolyte Blood Press 2007; 5: 68-74.
30. Rao R, Zhang MZ, Zhao M, Cai H, Harris RC, Breyer MD et al. Lithium treatment inhibits renal GSK-3 activity and promotes cyclooxygenase 2-dependent polyuria. Am J Physiol Renal Physiol 2005; 288: F642-F649.
31. Rao R, Hao CM, Breyer MD. Hypertonic stress activates glycogen synthase kinase 3beta-mediated apoptosis of renal medullary interstitial cells, suppressing an NFkB-driven cyclooxygenase-2-dependent survival pathway. J Biol Chem 2004; 279: 3949-3955.
32. Cipriani A, Hawton K, Stockton S, Geddes JR. Lithium in the prevention of suicide in mood disorders: updated systematic review and meta-analysis. BMJ 2013; 346: f3646.
33. Alvarez G, Munoz-Montano JR, Satrustegui J, Avila J, Bogonez E, Diaz-Nido J. Regulation of tau phosphorylation and protection against beta-amyloid-induced neurodegeneration by lithium. Possible implications for Alzheimer's disease. Bipolar Disord 2002; 4: 153-165.
34. Alvarez G, Munoz-Montano JR, Satrustegui J, Avila J, Bogonez E, Diaz-Nido J. Lithium protects cultured neurons against beta-amyloid-induced neurodegeneration. FEBS Lett 1999; 453: 260-264.
35. Stolk P, Souverein PC, Wilting I, Leufkens HG, Klein DF, Rapoport SI et al. Is aspirin useful in patients on lithium? A pharmacoepidemiological study related to bipolar disorder. Prostaglandins Leukot Essent Fatty Acids 2010; 82: 9-14.
36. Serhan CN, Hong S, Gronert K, Colgan SP, Devchand PR, Mirick G et al. Resolvins: a family of bioactive products of omega-3 fatty acid transformation circuits initiated by aspirin treatment that counter proinflammation signals. J Exp Med 2002; 196: 1025-1037.
37. Basselin M, Villacreses NE, Lee HJ, Bell JM, Rapoport SI. Chronic lithium administration attenuates up-regulated brain arachidonic acid metabolism in a rat model of neuroinflammation. J Neurochem 2007; 102: 761-772.
38. Basselin M, Kim HW, Chen M, Ma K, Rapoport SI, Murphy RC et al. Lithium modifies brain arachidonic and docosahexaenoic metabolism in rat lipopolysaccharide model of neuroinflammation. J Lipid Res 2010; 51: 1049-1056.
39. Jope RS. Lithium and GSK-3: one inhibitor, two inhibitory actions, multiple outcomes. Trends Pharmacol Sci 2003; 24: 441-443.
40. Griffin WS, Sheng JG, Royston MC, Gentleman SM, McKenzie JE, Graham DI et al. Glialneuronal interactions in Alzheimer's disease: the potential role of a 'cytokine cycle' in disease progression. Brain Pathol 1998; 8: 65-72.
41. Abbas N, Bednar I, Mix E, Marie S, Paterson D, Ljungberg A et al. Up-regulation of the inflammatory cytokines IFN-gamma and IL-12 and down-regulation of IL-4 in cerebral cortex regions of APP(SWE) transgenic mice. J Neuroimmunol 2002; 126: 50-57.
42. Brown GC, Bal-Price A. Inflammatory neurodegeneration mediated by nitric oxide, glutamate, and mitochondria. Mol Neurobiol 2003; 27: 325-355.
43. Griffin WS, Stanley LC, Ling C, White L, MacLeod V, Perrot LJ et al. Brain interleukin 1 and S-100 immunoreactivity are elevated in Down syndrome and Alzheimer disease. Proc Natl Acad Sci USA 1989; 86: 7611-7615.
44. van der Wal EA, Gomez-Pinilla F, Cotman CW. Transforming growth factor-beta 1 is in plaques in Alzheimer and Down pathologies. Neuroreport 1993; 4: 69-72.
45. Sy M, Kitazawa M, Medeiros R, Whitman L, Cheng D, Lane TE et al. Inflammation induced by infection potentiates tau pathological features in transgenic mice. Am J Pathol 2011; 178: 2811-2822.
46. De-Paula Vde J, Kerr DS, de Carvalho MP, Schaeffer EL, Talib LL, Gattaz WF et al. Long-Term Lithium Treatment Increases cPLA(2) and iPLA(2) Activity in Cultured Cortical and Hippocampal Neurons. Molecules 2015; 20: 19878-19885.
47. Nassar A, Azab AN. Effects of lithium on inflammation. ACS Chem Neurosci 2014; 5: 451-458.
48. Beurel E, Jope RS. Inflammation and lithium: clues to mechanisms contributing to suicide-linked traits. Transl Psychiatry 2014; 4: e488.
49. Valvassori SS, Tonin PT, Varela RB, Carvalho AF, Mariot E, Amboni RT et al. Lithium modulates the production of peripheral and cerebral cytokines in an animal model of mania induced by dextroamphetamine. Bipolar Disord 2015; 17: 507-517.
50. Giunta B, Rezai-Zadeh K, Tan J. Impact of the CD40-CD40L dyad in Alzheimer's disease. CNS Neurol Disord Drug Targets 2010; 9: 149-155.
51. Chen RW, Chuang DM. Long term lithium treatment suppresses p53 and Bax expression but increases Bcl-2 expression. A prominent role in neuroprotection against excitotoxicity. J Biol Chem 1999; 274: 6039-6042.
52. Chen G, Zeng WZ, Yuan PX, Huang LD, Jiang YM, Zhao ZH et al. The mood-stabilizing agents lithium and valproate robustly increase the levels of the neuroprotective protein bcl-2 in the CNS. J Neurochem 1999; 72: 879-882.
53. Town T, Vendrame M, Patel A, Poetter D, DelleDonne A, Mori T et al. Reduced Th1 and enhanced Th2 immunity after immunization with Alzheimer's beta-amyloid(1-42). J Neuroimmunol 2002; 132: 49-59.
54. Rezai-Zadeh K, Douglas Shytle R, Bai Y, Tian J, Hou H, Mori T et al. Flavonoid-mediated presenilin-1 phosphorylation reduces Alzheimer's disease beta-amyloid production. J Cell Mol Med 2009; 13: 574-588.
55. Zhu Y, Hou H, Rezai-Zadeh K, Giunta B, Ruscin A, Gemma C et al. CD45 deficiency drives amyloid-beta peptide oligomers and neuronal loss in Alzheimer's disease mice. J Neurosci 2011; 31: 1355-1365.
56. Tan J, Town T, Paris D, Mori T, Suo Z, Crawford F et al. Microglial activation resulting from CD40-CD40L interaction after beta-amyloid stimulation. Science 1999; 286: 2352-2355.
57. Saura J, Tusell JM, Serratosa J. High-yield isolation of murine microglia by mild trypsinization. Glia 2003; 44: 183-189.
58. Zhu Y, Obregon D, Hou H, Giunta B, Ehrhart J, Fernandez F et al. Mutant presenilin-1 deregulated peripheral immunity exacerbates Alzheimer-like pathology. J Cell Mol Med 2011; 15: 327-338.
59. Sawmiller D, Habib A, Li S, Darlington D, Hou H, Tian J et al. Diosmin reduces cerebral Abeta levels, tau hyperphosphorylation, neuroinflammation, and cognitive impairment in the 3xTg-AD mice. J Neuroimmunol 2016; 299: 98-106.
60. Sawmiller D, Li S, Mori T, Habib A, Rongo D, Delic V et al. Beneficial effects of a pyrroloquinolinequinone-containing dietary formulation on motor deficiency, cognitive decline and mitochondrial dysfunction in a mouse model of Alzheimer's disease. Heliyon 2017; 3: e00279.
61. Deng J, Habib A, Obregon DF, Barger SW, Giunta B, Wang YJ et al. Soluble amyloid precursor protein alpha inhibits tau phosphorylation through modulation of GSK3beta signaling pathway. J Neurochem 2015; 135: 630-637.